Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, Scali S, Hamzaj A, Derosa L, Felici A, Rossi M, Altavilla A, Chioni A, De Angelis V. Bracarda S, et al. Among authors: sisani m. Future Oncol. 2015 Nov;11(22):3083-90. doi: 10.2217/fon.15.217. Epub 2015 Oct 5. Future Oncol. 2015. PMID: 26437324
Biologic tools to personalize treatment in genitourinary cancers.
Bracarda S, Sisani M, Del Buono S, Ishiwa O, Montagnani F; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Bracarda S, et al. Among authors: sisani m. Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e42-8. doi: 10.1016/j.critrevonc.2010.09.008. Epub 2011 Jan 12. Crit Rev Oncol Hematol. 2012. PMID: 21232974 Review.
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, Altavilla A. Bracarda S, et al. Among authors: sisani m. Expert Rev Anticancer Ther. 2014 Nov;14(11):1283-94. doi: 10.1586/14737140.2014.965686. Epub 2014 Oct 29. Expert Rev Anticancer Ther. 2014. PMID: 25353258 Review.
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Bracarda S, et al. Among authors: sisani m. Ann Oncol. 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27. Ann Oncol. 2015. PMID: 26216384 Free article.
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Bracarda S, et al. Among authors: sisani m. Ann Oncol. 2016 Feb;27(2):366. doi: 10.1093/annonc/mdv589. Epub 2015 Dec 18. Ann Oncol. 2016. PMID: 26685011 Free article. No abstract available.
PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.
Francolini G, Porreca A, Facchini G, Santini D, Bruni A, Simoni N, Trovò M, Osti MF, Fornarini G, Sisani M, Di Cataldo V, Detti B, Garlatti P, Bertini N, Serni S, Minervini A, Livi L. Francolini G, et al. Among authors: sisani m. Med Oncol. 2023 Dec 29;41(1):39. doi: 10.1007/s12032-023-02268-3. Med Oncol. 2023. PMID: 38157111 Clinical Trial.
22 results